Hematologic Malignancies and Cellular Therapy

Danielle Marie Brander, MD

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 2400 Pratt St Suite 5000, Durham, NC 27710
Phone (919) 668-1000
Email address danielle.brander@duke.edu
In Their Words

Education and Training

  • Resident, Internal Medicine, Duke University School of Medicine, 2007 - 2010
  • M.D., Duke University School of Medicine, 2007

Grants

Publications

Mato, Anthony R., Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, et al. “A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL..” Blood Adv 3, no. 10 (May 28, 2019): 1568–73. https://doi.org/10.1182/bloodadvances.2019000180.

PMID
31101647
Full Text

Weinberg, J Brice, Danielle M. Brander, Dale J. Christensen, and Daphne R. Friedman. “Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al..” Br J Haematol, May 1, 2019. https://doi.org/10.1111/bjh.15934.

PMID
31044417
Full Text

Brander, Danielle M., Daphne R. Friedman, Alicia D. Volkheimer, Dale J. Christensen, Laura Z. Rassenti, Thomas J. Kipps, Eross Guadalupe, et al. “SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia..” British Journal of Haematology 184, no. 4 (February 2019): 605–15. https://doi.org/10.1111/bjh.15677.

PMID
30443898
Full Text

Wierda, William G., John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, et al. “NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019..” J Natl Compr Canc Netw 17, no. 1 (January 2019): 12–20. https://doi.org/10.6004/jnccn.2019.0002.

PMID
30659125
Full Text

Woyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, et al. “Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL..” N Engl J Med 379, no. 26 (December 27, 2018): 2517–28. https://doi.org/10.1056/NEJMoa1812836.

PMID
30501481
Full Text

Mato, Anthony R., Lindsey E. Roeker, John N. Allan, John M. Pagel, Danielle M. Brander, Brian T. Hill, Bruce D. Cheson, et al. “Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial..” Am J Hematol 93, no. 11 (November 2018): 1394–1401. https://doi.org/10.1002/ajh.25261.

PMID
30132965
Full Text

Mato, Anthony R., Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, et al. “Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States..” Haematologica 103, no. 9 (September 2018): 1511–17. https://doi.org/10.3324/haematol.2018.193615.

PMID
29880613
Full Text

Mato, Anthony R., Jennifer C. Samp, Geneviève Gauthier, Emi Terasawa, and Danielle M. Brander. “Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies..” Cancer Biol Ther 19, no. 7 (July 3, 2018): 636–43. https://doi.org/10.1080/15384047.2018.1449616.

PMID
29584544
Full Text

Mato, Anthony R., Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian Hill, Christina Howlett, et al. “Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis..” Haematologica 103, no. 5 (May 2018): 874–79. https://doi.org/10.3324/haematol.2017.182907.

PMID
29419429
Full Text

Burris, Howard A., Ian W. Flinn, Manish R. Patel, Timothy S. Fenske, Changchun Deng, Danielle M. Brander, Martin Gutierrez, et al. “Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study..” Lancet Oncol 19, no. 4 (April 2018): 486–96. https://doi.org/10.1016/S1470-2045(18)30082-2.

PMID
29475723
Full Text

Pages